OKUR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.39%, SMA50 -4.23%, SMA200 -0.96%). The stock’s 14-day RSI is 51.35 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.5% below its high and over 56.47% above its low. Average 10-day trading volume of 124.26 thousand shares is below the 3-month average of 296.74 thousand, indicating normal recent market interest.

OnKure Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.33. This means the shares are trading below this model’s fair value.

OnKure Therapeutics, Inc. generated EPS of -$6.17 over the past year. Five-year average earnings growth is 5.08%. Wall Street analysts project EPS growth of 41.07% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $34.00 to $21.00. The high target offers 790.05% upside. The low target suggests 449.74% downside. The mean target is $27.33. This offers 615.45% upside. OnKure Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 49.49%. The prior quarter beat by -13.91%. Over the last six quarters, Apple has recorded several small beats. These include 59.3% in March 10, 2025.

OnKure Therapeutics, Inc. has 12.84 million shares outstanding. The public float is 5.81 million shares, elevated short interest at 2.38% of float. This equals 225.95 thousand shares. The short ratio is 3.23 days. Institutional investors hold 85.72% of the float. Insiders own 10.48%. ACORN BIOVENTURES, L.P. holds 1.13 million shares, Leverone Jason A. has 18.80 thousand shares and Saccomano Nicholas A has 11.25 thousand shares. Over the past six months, insider transactions show net selling. They sold 776.00 shares across 4 transactions.

OnKure Therapeutics, Inc. trades at a P/E ratio of -0.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.28 suggesting the stock is closer to book value. The P/FCF stands at -1.03, also below market averages.

Our AI price prediction model suggests that OnKure Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.83%, with price expected at $3.75 by August 13, 2026, within a range of $3.62 to $3.87 3-Month Outlook: Projected rise of 15.45%, reaching $4.41 by October 28, 2026, with a range of $3.96 to $4.67. 1-Year Outlook: Projected gain of 177.49%, with price at $10.60 by July 30, 2027, within a range of $6.50 to $11.83.

OnKure Therapeutics, Inc. (NASDAQ:OKUR) shares are flat 2.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows OnKure Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.88. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $31.78, suggesting 731.94% upside. Our AI forecast model points to short-term weakness (-1.83% over two weeks), a medium-term rise (15.45% over three months), and a longer-term gain (177.49% over one year), with expected trading ranges indicating moderate volatility.

OnKure Therapeutics, Inc. (NASDAQ:OKUR) closed at $3.82 USD, losing -$0.18 (-4.50%) from the previous close of $4.00. The stock is currently mid-range between its 52-week high and low $1.91 and $5.38. With a market capitalization of about $52.23 million, OnKure Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 300.71 thousand shares, in line with its 52-week average. Headquartered in Boulder, CO, OnKure Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Nicholas A. Saccomano, the company employs approximately 45 people and listed since April 08, 2021. OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer.